Zhang Zhilan, Ma Chunyan, Luo Yanbing
Department of Ultrasonic Medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
J Gastrointest Oncol. 2023 Apr 29;14(2):626-635. doi: 10.21037/jgo-23-211. Epub 2023 Apr 24.
Hepatocellular carcinoma is the sixth most common cancer in the world, and its incidence rate will continue to increase. Contrast-enhanced ultrasound (CEUS) is feasible as a rapid examination for early hepatocellular carcinoma diagnosis. However, considering the possible causes of false positives caused by ultrasound, its diagnostic value is still controversial. Therefore, the study conducted a meta-analysis to evaluate the application value of CEUS in the early diagnosis of hepatocellular carcinoma.
The PubMed, Cochrane Library, Embase, Ovid Technologies (OVID), China National Knowledge Infrastructure (CNKI), Chongqing VIP Information (VIP), and Wanfang databases were searched to retrieve articles on the use of CEUS for the early diagnosis of hepatocellular carcinoma. The literature quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) quality assessment tool. The meta-analysis was performed using STATA 17.0 to fit the bivariate mixed effects model, calculated sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and corresponding 95% CI, summary receiver operating characteristic curves (SROC), area under the curve (AUC), and 95% confidence interval (CI). The publication bias of the included literature was evaluated using the DEEK funnel plot.
Ultimately, 9 articles, comprising 1,434 patients, were included in the meta-analysis. The heterogeneity test found that I>50%, using a random effects model. The results of the meta-analysis showed that the CEUS had a combined sensitivity of 0.92 (95% CI: 0.86-0.95), a combined specificity of 0.93 (95% CI: 0.56-0.99), a combined PLR of 13.47 (95% CI: 1.51-120.46), a combined NLR of 0.09 (95% CI: 0.05-0.14), a combined DOR of 154.16 (95% CI: 15.93-1,492.02), a diagnostic score of 5.04 (95% CI: 2.77-7.31), and a combined AUC of 0.95 (95% CI: 0.93-0.97). The correlation coefficient of the threshold-effect analysis was 0.13 (P>0.05). The results of the regression analysis showed that the country of publication (P=0.14) and the size of the lesion nodules (P=0.46) were not sources of heterogeneity.
Liver CEUS has an advantage in the early diagnosis of hepatocellular carcinoma, with high sensitivity and specificity, and has clinical application value.
肝细胞癌是全球第六大常见癌症,其发病率将持续上升。超声造影(CEUS)作为早期肝细胞癌诊断的快速检查方法是可行的。然而,考虑到超声可能导致假阳性的原因,其诊断价值仍存在争议。因此,本研究进行了一项荟萃分析,以评估CEUS在肝细胞癌早期诊断中的应用价值。
检索PubMed、Cochrane图书馆、Embase、Ovid Technologies(OVID)、中国知网(CNKI)、重庆维普资讯(VIP)和万方数据库,以获取关于使用CEUS进行肝细胞癌早期诊断的文章。使用诊断准确性研究质量评估2(QUADAS-2)质量评估工具进行文献质量评估。使用STATA 17.0进行荟萃分析,以拟合双变量混合效应模型,计算敏感性、特异性、阳性似然比(PLR)、阴性似然比(NLR)、诊断比值比(DOR)以及相应的95%置信区间(CI)、汇总接收器操作特征曲线(SROC)、曲线下面积(AUC)和95%置信区间(CI)。使用DEEK漏斗图评估纳入文献的发表偏倚。
最终,9篇文章(共1434例患者)纳入荟萃分析。异质性检验发现I>50%,采用随机效应模型。荟萃分析结果显示,CEUS的合并敏感性为0.92(95%CI:0.86-0.95),合并特异性为0.93(95%CI:0.56-0.99),合并PLR为13.47(95%CI:1.51-120.46),合并NLR为0.09(95%CI:0.05-0.14),合并DOR为154.16(95%CI:15.93-1492.02),诊断评分为5.04(95%CI:2.77-7.31),合并AUC为0.95(95%CI:0.93-0.97)。阈值效应分析的相关系数为0.13(P>0.05)。回归分析结果显示,发表国家(P=0.14)和病变结节大小(P=0.46)不是异质性来源。
肝脏CEUS在肝细胞癌早期诊断中具有优势,具有高敏感性和特异性,具有临床应用价值。